EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing Real World Efficacy, Safety, and 18‐Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies

Nicole Chemaly iD, Mathieu Kuchenbuch iD, Emma Losito, Anna Kaminska iD, Delphine Coste-Zeitoun iD, Giulia Barcia iD, Isabelle Desguerre iD, Marie Hully iD, Rima Nabbout iD

European Journal of Neurology · 2025

DOI: 10.1111/ene.70304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Nicole Chemaly und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Reference Center for Rare Epilepsies, Hôpital Necker-Enfants Malades, Member of ERN EpiCARE, Paris, France. Hauptthemen laut MEDLINE: Cannabidiol, Drug Resistant Epilepsy, Anticonvulsants. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, FAMA, Swiss Philanthropy Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Highly purified Cannabidiol (CBD, epidiolex) is approved for treating Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis (TSC), with off‐label use in drug‐resistant epilepsies. The aim of this study is to evaluate efficacy, safety, and long‐term retention of CBD in a large pediatric population.

Methods

We prospectively included all consecutive patients initiating CBD for drug‐resistant epilepsy at our pediatric tertiary center from 2019 to 2021. Efficacy and safety were assessed via parental questionnaires on seizure and non‐seizure outcomes at 1, 2, and 6 months, comparing each item to prior clinic visits. Retention rate was evaluated at 18 months.

Results

We included 103 patients (mean age 11.2 years), with 47% receiving CBD for label‐approved syndromes (23 DS, 15 LGS, 10 TSC) and 53% off‐label. At 1 month, 54% of caregivers reported reduced seizure frequency and duration, with a positive overall impression in 62%. By months 2–6, 48% maintained seizure improvement, alongside sustained gains in communication (60%), alertness (54%), and motor skills (44%). Retention rates were 97% at 1 month, 90% at 2 months, 82% at 6 months, 66% at 12 months, and 55% at 18 months. Off‐label use ( p = 0.02), male gender ( p = 0.049), and older age at initiation ( p = 0.03) were associated with higher retention.

Conclusions

CBD reduced seizures and improved non seizures' morbidities in drug‐resistant epilepsy. Strong 18‐month retention rate, including off‐label use, highlights efficacy and tolerability, underscoring the need for further real‐world data in various rare epilepsy syndromes beyond its market approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolDrug Resistant EpilepsyAnticonvulsantsHumansMaleFemaleChildAdolescentProspective StudiesChild, PreschoolEpilepsies, MyoclonicTreatment OutcomeLennox Gastaut Syndrome

Stichwörter der Autor:innen

Dravet syndromeLennox–Gastaut syndromedevelopmental and epileptic encephalopathygender differencesoff‐labelretention ratetuberous sclerosis

Substanzen

CannabidiolAnticonvulsants

Autor:innen und Institutionen

  • Department of Pediatric Neurology, Reference Center for Rare Epilepsies, Hôpital Necker-Enfants Malades, Member of ERN EpiCARE, Paris, France.
  • Université de Lorraine, CNRS, IMoPA, F-54000 Nancy, France.
  • Service de Pédiatrie, Reference Center for Rare Epilepsies, Member of ERN EpiCARE, Université de Lorraine, CHRU-Nancy, F-54000 Nancy, France.
  • Unit of Pediatric Neurophysiology, Necker Enfants Malades Hospital, AP-HP, Paris, France.
  • Université de Paris Cité, Paris, France.
  • Laboratory of Translational Research for Neurological Disorders, INSERM MR1163, Imagine Institute, Paris, France.

ORCID-Profile: Nicole Chemaly, Mathieu Kuchenbuch, Anna Kaminska, Delphine Coste-Zeitoun, Giulia Barcia, Isabelle Desguerre, Marie Hully, Rima Nabbout

Förderung

  • Agence Nationale de la Recherche
  • FAMA
  • Swiss Philanthropy Foundation

Zitieren

APA

Chemaly, N., Kuchenbuch, M., Losito, E., Kaminska, A., Coste-Zeitoun, D., Barcia, G., Desguerre, I., Hully, M., & Nabbout, R. (2025). Assessing Real World Efficacy, Safety, and 18‐Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies. European Journal of Neurology. https://doi.org/10.1111/ene.70304

Vancouver

Chemaly N, Kuchenbuch M, Losito E, Kaminska A, Coste-Zeitoun D, Barcia G, et al. Assessing Real World Efficacy, Safety, and 18‐Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies. European Journal of Neurology. 2025. doi:10.1111/ene.70304

BibTeX
@article{Chemaly2025,
  author = {Chemaly, Nicole and Kuchenbuch, Mathieu and Losito, Emma and Kaminska, Anna and Coste-Zeitoun, Delphine and Barcia, Giulia and Desguerre, Isabelle and Hully, Marie and Nabbout, Rima},
  title = {Assessing Real World Efficacy, Safety, and 18‐Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70304}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche